VERONA PHARMA PLC (VRP)

This year’s Verona Pharma AGM was held at 9.00 a.m. on Wednesday 2nd May 2018 at The London offices of NASDAQ, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA For investors who are unfamiliar with the company, Verona is a clinical stage Pharmaceutical company currently focused on developing just one asset, RPL554, which has a unique mechanism of action (PDE3/PDE4 inhibition). RPL554 is currently being developed for the treatment of COPD and Cystic Fibrosis. The company listed on Aim in 2006 through a ...

I attended the Verona Pharma AGM on Monday (June 27th) which was held at the offices of Shakespeare Martineau LLP, 5th Floor, One America Square, Crosswall, London EC3N 2SG. For anyone who is unfamiliar with the company, Verona Pharma (VRP) are an AIM listed UK based biotech focused on developing new treatments for COPD, Asthma and other respiratory diseases. Their current market cap is around £32M and they have just one compound (RPL554) in their portfolio which is being developed primarily for ...